Search Results - "Mailman, Josh"

The ICPO Foundation—on the way toward collaborative growth of theranostics by Baum, Richard P., Mailman, Josh, Jaume, Odile

Get full text

Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors by Hope, Thomas A, Bergsland, Emily K, Bozkurt, Murat Fani, Graham, Michael, Heaney, Anthony P, Herrmann, Ken, Howe, James R, Kulke, Matthew H, Kunz, Pamela L, Mailman, Josh, May, Lawrence, Metz, David C, Millo, Corina, O'Dorisio, Sue, Reidy-Lagunes, Diane L, Soulen, Michael C, Strosberg, Jonathan R

“…Somatostatin receptor (SSTR) PET has demonstrated a significant improvement over conventional imaging (CI) in patients with neuroendocrine tumors (NETs). SSTR…”
Get full text

Researcher Experience and Comfort With Telemedicine and Remote Patient Monitoring in Cancer Treatment Trials by Lichtenstein, Morgan R L, Levit, Laura A, Schenkel, Caroline, Kirkwood, Kelsey, Fashoyin-Aje, Lola A, Bruinooge, Suanna S, Kelley, Michael J, Mailman, Josh A, Magnuson, Allison, Mirda, Daniel P, Natesan, Divya, Hershman, Dawn L

“…Since the onset of COVID-19, oncology practices across the US have integrated telemedicine (TM) and remote patient monitoring (RPM) into routine care and…”
Get full text

Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET by Singh, Simron, Ferone, Diego, Capdevila, Jaume, Chan, Jennifer Ang, de Herder, Wouter W, Halperin, Daniel, Mailman, Josh, Hellström, Lisa, Liedman, Hanna, Svedberg, Agneta, Tiberg, Fredrik

“…The current standard of care (SoC) for the initial treatment of unresectable or metastatic well-differentiated gastroenteropancreatic neuroendocrine tumours…”
Get full text

Patient Travel Concerns After Treatment with 177 Lu-DOTATATE by Kendi, Ayşe Tuba, Mailman, Josh A, Naraev, Boris G, Mercer, David J, Underwood, James K, Halfdanarson, Thorvardur R

Get full text

Correction: Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET by Singh, Simron, Ferone, Diego, Capdevila, Jaume, Chan, Jennifer Ang, de Herder, Wouter W, Halperin, Daniel, Mailman, Josh, Hellström, Lisa, Liedman, Hanna, Svedberg, Agneta, Tiberg, Fredrik

Get full text

Improving Tools and Options for the Management of Patients with Neuroendocrine Tumors: A Patient Perspective by Mailman, Josh

Get full text

A Patients’ Perspective on Integrative Oncology: Getting Past the “War,” Living With and Beyond Cancer by Mailman, Josh

Get full text

Leadership in Patient Advocacy: A Conversation Between Josh Mailman and Thomas Hope by Mailman, Josh, Hope, Thomas A

Get full text

A Comprehensive Definition for Integrative Oncology by Witt, Claudia M., Balneaves, Lynda G., Cardoso, Maria J., Cohen, Lorenzo, Greenlee, Heather, Johnstone, Peter, Kücük, Ömer, Mailman, Josh, Mao, Jun J.

“…Abstract Background Integrative oncology, which is generally understood to refer to the use of a combination of complementary medicine therapies in conjunction…”
Get full text

Genetic profiling analysis design of well-differentiated aggressive grade 2 and 3 gastroenteropancreatic neuroendocrine tumors in the phase III randomized controlled COMPOSE trial by Halfdanarson, Thorvardur Ragnar, Capdevila, Jaume, Halperin, Daniel M., Herrmann, Ken, Kong, Grace, Leyden, Simone, Mailman, Josh, Reidy-Lagunes, Diane, Srirajaskanthan, Rajaventhan, Erdö, Máté, Rotger, Amanda, Thevenet, Thomas

“…TPS660 Background: Deeper comprehension of gastroenteropancreatic neuroendocrine tumor (GEP-NET) characteristics has led to development of therapeutic…”
Get full text

Methodology of the SORENTO clinical trial: Assessing the efficacy and safety of high exposure octreotide subcutaneous depot in patients with GEP-NETs by Singh, Simron, Capdevila, Jaume, Chan, Jennifer A., de Herder, Wouter, Ferone, Diego, Halperin, Daniel M., Mailman, Josh, Dorkhan, Mozhgan, Hellström, Lisa, Svedberg, Agneta, Tiberg, Fredrik

“…TPS4178 Background: Somatostatin receptor ligands (SRLs) are first-line standard of care therapies for gastroenteropancreatic neuroendocrine tumors (GEP-NETs),…”
Get full text

Practical considerations when providing palliative care to patients with neuroendocrine tumors in the context of routine disease management or hospice care by Del Rivero, Jaydira, Mailman, Josh, Rabow, Michael W, Chan, Jennifer A, Creed, Sarah, Kennecke, Hagen F, Pasieka, Janice, Zuar, Jennifer, Singh, Simron, Fishbein, Lauren

“…This serves as a white paper by the North American Neuroendocrine Tumor Society (NANETS) on the practical considerations when providing palliative care to…”
Get full text

Patient Travel Concerns After Treatment with 177Lu-DOTATATE by Kendi, Ayşe Tuba, Mailman, Josh A, Naraev, Boris G, Mercer, David J, Underwood, James K, Halfdanarson, Thorvardur R

Get full text

Researcher experience and comfort with telemedicine and remote patient monitoring in cancer treatment trials by Lichtenstein, Morgan RL, Levit, Laura, Schenkel, Caroline, Kirkwood, Margaret Kelsey, Kelley, Michael J., Mailman, Josh, Magnuson, Allison, Mirda, Daniel P., Natesan, Divya, Fashoyin-Aje, Lola A., Hershman, Dawn L.

“…385 Background: Since the onset of COVID-19, oncology practices across the U.S. have integrated telemedicine (TM) and remote patient monitoring (RPM) into…”
Get full text

Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline by Del Rivero, Jaydira, Perez, Kimberly, Kennedy, Erin B, Mittra, Erik S, Vijayvergia, Namrata, Arshad, Junaid, Basu, Sandip, Chauhan, Aman, Dasari, Arvind N, Bellizzi, Andrew M, Gangi, Alexandra, Grady, Erin, Howe, James R, Ivanidze, Jana, Lewis, Mark, Mailman, Josh, Raj, Nitya, Soares, Heloisa P, Soulen, Michael C, White, Sarah B, Chan, Jennifer A, Kunz, Pamela L, Singh, Simron, Halfdanarson, Thorvardur R, Strosberg, Jonathan R, Bergsland, Emily K

“…To develop recommendations for systemic therapy for well-differentiated grade 1 (G1) to grade 3 (G3) metastatic gastroenteropancreatic neuroendocrine tumors…”
Get full text

Consideration of quality of life in the treatment decision-making for patients with advanced gastroenteropancreatic neuroendocrine tumors by Naraev, Boris G., Mailman, Josh, Halfdanarson, Thorvardur R., Soares, Heloisa P., Mittra, Erik S., Hallet, Julie

“…Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a complex and heterogenous family of solid malignancies that originate from neuroendocrine tissue…”
Get full text

A Framework for Patient-Centered Pathways of Care for Radiopharmaceutical Therapy: An ASTRO Consensus Document by Buatti, John M., Pryma, Daniel A., Kiess, Ana P., Mailman, Josh, Ennis, Ronald D., Menda, Yusuf, White, Gerald A., Pandit-Taskar, Neeta

“…Radiopharmaceutical therapy (RPT) is an area of projected growth and importance with several agents in clinical use, new agents in late-phase clinical trials,…”
Get full text

Making progress against rare cancers: A case study on neuroendocrine tumors by O’Rorke, Michael, Chrischilles, Elizabeth, Chamberlain, Alanna M., Chrischilles, Elizabeth A., Cowell, Lindsay G., Dillon, Joseph S., Early, Carol, Else, Tobias, Gamblin, T. Clark, Geller, David, Gellerman, Elyse, Gryzlak, Brian, Halfdanarson, Thorvardur R., Hamilton, Harley C., He, Fiona C., Hourcade, Juan Pablo, Indrees, Kamran, Kazmi, Syed M., Lancaster, William, Lewis‐Hughes, Amoni, Liu, Mei, Mailman, Josh A., McDowell, Bradley, O’Rorke, Michael, Ramirez, Robert A., Ramnaraign, Brian H., Sanoff, Hanna K., Soares, Heloisa P., Sukrithan, Vineeth, Taylor, Bradley W., Tepper, Mia S., Wahmann, Maryann, Zamba, Gideon K. D.

“…In April 2023, the National Cancer Institute offered a roadmap for cancer research to achieve Cancer Moonshot goals. To reach these goals requires making…”
Get full text

Education Competencies for Integrative Oncology—Results of a Systematic Review and an International and Interprofessional Consensus Procedure by Witt, Claudia M., Balneaves, Lynda G., Carlson, Linda E., Cohen, Misha, Deng, Gary, Fouladbakhsh, Judith M., Kinney, Anita Y., Mehta, Ashwin, Mailman, Josh, Pole, Laura, Rogge, Alizé A., O’Toole, Carole, Zick, Suzanna M., Helmer, Stefanie M.

“…Integrative oncology is a burgeoning field and typically provided by a multiprofessional team. To ensure cancer patients receive effective, appropriate, and…”
Get full text